Conclusion
In this study, the molecular mechanisms and related pathways that may
cause clinical severity among mild and severe CF siblings with same
genotype were identified. The data obtained as a result of this study
will provide opportunity for identification and development of new
target molecules for treatment in the future. Also determination of
candidate genes will pave the way for their use for both prognostic and
therapeutic biomarkers especially for preventing the progression of
hepatic involvement. Determination of differentially expressed genes and
associated pathways between CF patients and controls may provide new
insights into molecular pathology of not only CF but also other
respiratory diseases.